Axonal transection in the lesions of multiple sclerosis.
暂无分享,去创建一个
R. Rudick | B. Trapp | J. Peterson | R. Ransohoff | S. Mörk | L. Bö | S. Mørk | L. Bø | Bruce D. Trapp | Lars Bø
[1] M. Bornstein,et al. Functional Studies of Cultured Brain Tissues as Related to "Demyelinative Disorders" , 1965, Science.
[2] W. Norton,et al. MYELINATION IN RAT BRAIN: METHOD OF MYELIN ISOLATION 1 , 1973, Journal of neurochemistry.
[3] R. Lasek,et al. The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons , 1975, The Journal of cell biology.
[4] I. A. Boyd,et al. Ultrastructural dimensions of myelinated peripheral nerve fibres in the cat and their relation to conduction velocity , 1980, The Journal of physiology.
[5] J. Prineas,et al. Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown , 1981, Annals of neurology.
[6] L. Sternberger,et al. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[7] N. Hirokawa,et al. Organization of mammalian neurofilament polypeptides within the neuronal cytoskeleton , 1984, Journal of Cell Biology.
[8] E. Cho,et al. Continual Breakdown and Regeneration of Myelin in Progressive Multiple Sclerosis Plaques a , 1984, Annals of the New York Academy of Sciences.
[9] A. Windebank,et al. Myelination determines the caliber of dorsal root ganglion neurons in culture , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[10] J. Trojanowski,et al. Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[11] J. Trojanowski,et al. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[12] R. Newcombe,et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[13] B. Trapp,et al. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes , 1989, The Journal of cell biology.
[14] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[15] A. Cross,et al. Axonal dystrophy as a consequence of long-term demyelination. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[16] B Bacci,et al. Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease. , 1991, The American journal of pathology.
[17] C. Brosnan,et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.
[18] T. Kitamoto,et al. Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions , 1992, Neuroscience Letters.
[19] Scott T. Brady,et al. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells , 1992, Cell.
[20] Roland Martin,et al. Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.
[21] D. Graham,et al. β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury , 1993, Neuroscience Letters.
[22] D. Hanley,et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains , 1994, Annals of neurology.
[23] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[24] B. Trapp,et al. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions , 1994, Journal of Neuroimmunology.
[25] W. Mcdonald. RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.
[26] P. Matthews,et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.
[27] A. Thompson,et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.
[28] P. Matthews,et al. Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.
[29] N. Hirokawa,et al. Two distinct functions of the carboxyl-terminal tail domain of NF-M upon neurofilament assembly: cross-bridge formation and longitudinal elongation of filaments , 1995, The Journal of cell biology.
[30] M. Schachner,et al. Crucial Role for the Myelin‐associated Glycoprotein in the Maintenance of Axon‐Myelin Integrity , 1995, The European journal of neuroscience.
[31] P. Matthews,et al. Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.
[32] M. Namboodiri,et al. N-acetylaspartate as an acetyl source in the nervous system. , 1995, Brain research. Molecular brain research.
[33] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[34] J. Haines,et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.
[35] P. Goodfellow,et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.
[36] P M Matthews,et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.
[37] R. Nixon,et al. Oligodendroglia Regulate the Regional Expansion of Axon Caliber and Local Accumulation of Neurofilaments during Development Independently of Myelin Formation , 1996, The Journal of Neuroscience.
[38] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[39] D. Hinds,et al. A full genome search in multiple sclerosis , 1996, Nature Genetics.
[40] B. Trapp,et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. , 1996, Journal of neuropathology and experimental neurology.
[41] B. Weinshenker,et al. Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.
[42] A. Thompson,et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.
[43] B. Trapp,et al. Differentiation and Death of Premyelinating Oligodendrocytes in Developing Rodent Brain , 1997, The Journal of cell biology.
[44] R. Hohlfeld,et al. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.
[45] P. Matthews,et al. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.
[46] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.